Citigroup
VRCA icon

Citigroup’s Verrica Pharmaceuticals VRCA Stock Holding History

Citigroup’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,065
Closed -$8.9K – 6508
2025
Q3 		$8.9K Buy
2,065
+1,725
+507% +$10.4K ﹤0.01% 5059
2025
Q2 		$1.8K Sell
340
-2,571
-88% -$13.8K ﹤0.01% 5367
2025
Q1 		$12.9K Buy
2,911
+1,393
+92% +$9.01K ﹤0.01% 5157
2024
Q4 		$10.6K Buy
1,518
+151
+11% +$1.66K ﹤0.01% 5373
2024
Q3 		$19.8K Buy
1,367
+918
+204% +$41.3K ﹤0.01% 5190
2024
Q2 		$32.7K Buy
449
+68
+18% +$5.22K ﹤0.01% 4813
2024
Q1 		$22.5K Buy
381
+83
+28% +$4.58K ﹤0.01% 4995
2023
Q4 		$21.8K Buy
298
+296
+14,800% +$12.2K ﹤0.01% 4961
2023
Q3 		$78 Sell
2
-620
-100% -$31.5K ﹤0.01% 5464
2023
Q2 		$35.9K Sell
622
-503
-45% -$30.5K ﹤0.01% 4799
2023
Q1 		$73.1K Buy
+1,125
New +$68K ﹤0.01% 4141
2022
Q4 		– Sell
-30
Closed -$1K – 5971
2022
Q3 		$1K Sell
30
-94
-76% -$3.22K ﹤0.01% 5703
2022
Q2 		$2K Buy
124
+18
+17% +$905 ﹤0.01% 5927
2022
Q1 		$9K Sell
106
-324
-75% -$26.7K ﹤0.01% 5598
2021
Q4 		$39K Buy
430
+267
+164% +$30.2K ﹤0.01% 5188
2021
Q3 		$20K Buy
163
+101
+163% +$11.3K ﹤0.01% 5241
2021
Q2 		$7K Sell
62
-20
-24% -$2.42K ﹤0.01% 5777
2021
Q1 		$12K Sell
82
-168
-67% -$23.2K ﹤0.01% 5561
2020
Q4 		$29K Buy
250
+190
+317% +$17.5K ﹤0.01% 6422
2020
Q3 		$5K Sell
60
-118
-66% -$9.67K ﹤0.01% 7050
2020
Q2 		$20K Sell
178
-188
-51% -$21.7K ﹤0.01% 6627
2020
Q1 		$40K Buy
366
+107
+41% +$14.1K ﹤0.01% 6181
2019
Q4 		$41K Buy
259
+161
+164% +$23.8K ﹤0.01% 6469
2019
Q3 		$14K Sell
98
-244
-71% -$27.2K ﹤0.01% 6929
2019
Q2 		$39K Buy
342
+55
+19% +$5.16K ﹤0.01% 6696
2019
Q1 		$31K Buy
287
+121
+73% +$14K ﹤0.01% 6723
2018
Q4 		$13K Buy
166
+4
+2% +$486 ﹤0.01% 7068
2018
Q3 		$26K Buy
+162
New +$27.7K ﹤0.01% 6962

Other funds holding VRCA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citigroup's VRCA Position: Q4 2025 in Review

Citigroup sold out of Verrica Pharmaceuticals (VRCA) in Q4 2025, closing a stake of 2,065 shares — an estimated $8.9K sold.

Citigroup first reported a position in VRCA in Q3 2018 and held it in 28 quarters. The position peaked at $73.1K in Q1 2023. 50 funds tracked by Wall St. Rank hold VRCA as of Q4 2025.

  • Citigroup reported no remaining Verrica Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Citigroup sold 2,065 Verrica Pharmaceuticals shares in Q4 2025, an estimated $8.9K.
  • Citigroup first reported a position in Verrica Pharmaceuticals in Q3 2018 and held it in 28 quarters.
  • Citigroup's Verrica Pharmaceuticals position peaked at $73.1K in Q1 2023.
  • 50 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.